Literature DB >> 23695035

Disability and quality of life in headache: where we are now and where we are heading.

D D'Amico1, L Grazzi, S Usai, M Leonardi, A Raggi.   

Abstract

Headache disorders determine relevant personal and societal burden, and thus the use of patient-reported outcome measures (PROMs) investigating the level of disability and health-related quality of life (HRQoL) have been increasingly used in headache research. The aim of this review was to address the status of research on disability and HRQoL, by addressing results from recently published clinical trials as well as in longitudinal observational studies on headache patients. PubMed has been searched for papers in which measures of HRQoL and/or disability were used as primary or secondary outcome on adult subjects with primary headache, and published in 2010-2012. Among the 70 records retrieved, 12 papers were selected for narrative synthesis. They included data on 2,621 patients with episodic migraine with and without aura, chronic daily headache, and/or chronic migraine with and without medication overuse. The selected trials investigated the efficacy of different pharmacological prophylaxis, of some surgical approaches, of education programmes and osteopathic manipulative treatment; two studies reported longitudinal observations of patients currently under treatment. Overall, the results of our review showed that headache frequency as well as HRQoL and disability were positively impacted by treatment interventions; positive outcomes were less evident in two studies, and similar results were found in the two observational studies. Our findings confirmed that the most commonly used PROMs, including disease-specific tools to assess disability and HRQoL and SF-36, are sensitive to the beneficial effects occurring over time in functioning and quality of life domains in headache patients. They also suggest that the personal and societal costs of headache disorders are likely to be reduced when headache patients receive appropriate treatments and when continuity of care is offered. In terms of future directions, we note that the systematic use of appropriate PROMs should be encouraged both in the clinical practice and in the research field, as they offer a valid option to assess the global effect of treatments on patient-perceived sense of well-being and quality of performance.

Entities:  

Mesh:

Year:  2013        PMID: 23695035     DOI: 10.1007/s10072-013-1378-9

Source DB:  PubMed          Journal:  Neurol Sci        ISSN: 1590-1874            Impact factor:   3.307


  24 in total

1.  Psychiatric comorbidity and response to preventative therapy in the treatment of severe migraine trial.

Authors:  Elizabeth K Seng; Kenneth A Holroyd
Journal:  Cephalalgia       Date:  2012-03-09       Impact factor: 6.292

Review 2.  Disability in chronic daily headache: state of the art and future directions.

Authors:  Domenico D'Amico; L Grazzi; S Usai; A Raggi; M Leonardi; G Bussone
Journal:  Neurol Sci       Date:  2011-05       Impact factor: 3.307

3.  Development and validation of the Migraine-Specific Quality of Life Questionnaire.

Authors:  P Jhingran; J T Osterhaus; D W Miller; J T Lee; L Kirchdoerfer
Journal:  Headache       Date:  1998-04       Impact factor: 5.887

4.  Changes in headache frequency in premenopausal obese women with migraine after bariatric surgery: a case series.

Authors:  V Novack; L Fuchs; L Lantsberg; S Kama; U Lahoud; A Horev; N Loewenthal; G Ifergane
Journal:  Cephalalgia       Date:  2011-06-23       Impact factor: 6.292

5.  A socioeconomic analysis of surgical treatment of migraine headaches.

Authors:  Carey Faber; Ryan M Garcia; Janine Davis; Bahman Guyuron
Journal:  Plast Reconstr Surg       Date:  2012-04       Impact factor: 4.730

6.  Value and utility of disease-specific and generic instruments for assessing disability in patients with migraine, and their relationships with health-related quality of life.

Authors:  Alberto Raggi; Matilde Leonardi; Gennaro Bussone; Domenico D'Amico
Journal:  Neurol Sci       Date:  2010-12-14       Impact factor: 3.307

7.  Efficacy of osteopathic manipulative treatment of female patients with migraine: results of a randomized controlled trial.

Authors:  Karen Voigt; Jan Liebnitzky; Ute Burmeister; Henna Sihvonen-Riemenschneider; Matthias Beck; Roger Voigt; Antje Bergmann
Journal:  J Altern Complement Med       Date:  2011-03-08       Impact factor: 2.579

8.  A 3-month analysis of disability, quality of life, and disease course in patients with migraine.

Authors:  Alberto Raggi; Matilde Leonardi; Gennaro Bussone; Domenico D'Amico
Journal:  Headache       Date:  2012-10-24       Impact factor: 5.887

Review 9.  Adherence to acute migraine medication: what does it mean, why does it matter?

Authors:  Bozena J Katić; Steven J Krause; Stewart J Tepper; Henry X Hu; Marcelo E Bigal
Journal:  Headache       Date:  2009-10-08       Impact factor: 5.887

Review 10.  Assessing and managing all aspects of migraine: migraine attacks, migraine-related functional impairment, common comorbidities, and quality of life.

Authors:  Dawn C Buse; Marcia F T Rupnow; Richard B Lipton
Journal:  Mayo Clin Proc       Date:  2009-05       Impact factor: 7.616

View more
  12 in total

Review 1.  Assessment of Quality of Life in Migraine.

Authors:  Özlem Taşkapilioğlu; Necdet Karli
Journal:  Noro Psikiyatr Ars       Date:  2013-08-01       Impact factor: 1.339

2.  Psychosocial difficulties in patients with episodic migraine: a cross-sectional study.

Authors:  Alberto Raggi; Venusia Covelli; Silvia Schiavolin; Ambra M Giovannetti; Milda Cerniauskaite; Rui Quintas; Matilde Leonardi; Carla Sabariego; Licia Grazzi; Domenico D'Amico
Journal:  Neurol Sci       Date:  2016-09-09       Impact factor: 3.307

Review 3.  Types of nasal delivery drugs and medications in Iranian traditional medicine to treatment of headache.

Authors:  Zahra Ghorbanifar; Hosein Delavar Kasmaei; Bagher Minaei; Hossein Rezaeizadeh; Farid Zayeri
Journal:  Iran Red Crescent Med J       Date:  2014-06-05       Impact factor: 0.611

4.  Disability and quality of life in patients with different forms of migraine.

Authors:  Domenico D'Amico; Matilde Leonardi; Licia Grazzi; Marcella Curone; Alberto Raggi
Journal:  J Headache Pain       Date:  2015-12       Impact factor: 7.277

5.  Intravenous ketamine for subacute treatment of refractory chronic migraine: a case series.

Authors:  Clinton Lauritsen; Santiago Mazuera; Richard B Lipton; Sait Ashina
Journal:  J Headache Pain       Date:  2016-11-22       Impact factor: 7.277

6.  Mid-term sustained relief from headaches after balloon angioplasty of the internal jugular veins in patients with multiple sclerosis.

Authors:  Clive B Beggs; Alessia Giaquinta; Massimiliano Veroux; Ester De Marco; Dovile Mociskyte; Pierfrancesco Veroux
Journal:  PLoS One       Date:  2018-01-23       Impact factor: 3.240

7.  Two randomized migraine studies of galcanezumab: Effects on patient functioning and disability.

Authors:  Janet H Ford; David W Ayer; Qi Zhang; Jeffrey N Carter; Elizabeth Leroux; Vladimir Skljarevski; Sheena K Aurora; Antje Tockhorn-Heidenreich; Richard B Lipton
Journal:  Neurology       Date:  2019-07-03       Impact factor: 9.910

8.  Influence of hydrotherapy on clinical and cardiac autonomic function in migraine patients.

Authors:  M U Sujan; M Raghavendra Rao; Ravikiran Kisan; Hulegar A Abhishekh; Atchayaram Nalini; Trichur R Raju; T N Sathyaprabha
Journal:  J Neurosci Rural Pract       Date:  2016 Jan-Mar

9.  Validation of a self-reported instrument to assess work-related difficulties in patients with migraine: the HEADWORK questionnaire.

Authors:  Alberto Raggi; Venusia Covelli; Erika Guastafierro; Matilde Leonardi; Chiara Scaratti; Licia Grazzi; Marco Bartolini; Giovanna Viticchi; Sabina Cevoli; Giulia Pierangeli; Gioacchino Tedeschi; Antonio Russo; Piero Barbanti; Cinzia Aurilia; Carlo Lovati; Luca Giani; Fabio Frediani; Paola Di Fiore; Francesco Bono; Laura Rapisarda; Domenico D'Amico
Journal:  J Headache Pain       Date:  2018-09-10       Impact factor: 7.277

10.  Shift from high-frequency to low-frequency episodic migraine in patients treated with Galcanezumab: results from two global randomized clinical trials.

Authors:  Jakub Jedynak; Eric Eross; Astrid Gendolla; Mallikarjuna Rettiganti; Virginia L Stauffer
Journal:  J Headache Pain       Date:  2021-05-28       Impact factor: 7.277

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.